These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38958805)

  • 1. ASO Visual Abstract: Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Retrospective Study.
    Li J; Wang Q
    Ann Surg Oncol; 2024 Jul; ():. PubMed ID: 38958805
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer after Neoadjuvant Chemoradiotherapy: A Retrospective Study.
    Li J; Zhou X; Liu Y; Zhu J; Wan G; Wang Y; Leng X; Han Y; Peng L; Wu L; Wang Q
    Ann Surg Oncol; 2024 Jun; 31(6):3803-3812. PubMed ID: 38280959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASO Author Reflections: Fathoming the Dilemma of the Optimal Time to Surgery for Patients with Resectable Esophageal Cancer After Neoadjuvant Chemoradiotherapy.
    Li J; Wang Q
    Ann Surg Oncol; 2024 Jun; 31(6):3852-3853. PubMed ID: 38270832
    [No Abstract]   [Full Text] [Related]  

  • 4. Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial.
    Yang J; Huang A; Yang K; Jiang K
    BMC Cancer; 2023 Mar; 23(1):249. PubMed ID: 36922805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.
    Klevebro F; Nilsson K; Lindblad M; Ekman S; Johansson J; Lundell L; Ndegwa N; Hedberg J; Nilsson M
    Dis Esophagus; 2020 May; 33(5):. PubMed ID: 31676895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.
    Chan KKW; Saluja R; Delos Santos K; Lien K; Shah K; Cramarossa G; Zhu X; Wong RKS
    Int J Cancer; 2018 Jul; 143(2):430-437. PubMed ID: 29441562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients.
    Yuan M; Bao Y; Ma Z; Men Y; Wang Y; Hui Z
    Front Oncol; 2021; 11():628706. PubMed ID: 33777777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Tang H; Jiang D; Zhang S; Zeng Z; Tan L; Hou Y; Wang Q; ; Wang H; Zhu J; Shen Y; Yin J; Ge D
    J Thorac Cardiovasc Surg; 2021 Dec; 162(6):1632-1641. PubMed ID: 33268125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy
    Nakashima Y; Saeki H; Hu Q; Tsuda Y; Hisamatsu Y; Ando K; Oki E; Maehara Y
    Anticancer Res; 2018 Dec; 38(12):6809-6814. PubMed ID: 30504394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
    Versteijne E; van Dam JL; Suker M; Janssen QP; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Tienhoven G; van Eijck CHJ;
    J Clin Oncol; 2022 Apr; 40(11):1220-1230. PubMed ID: 35084987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
    Janssen QP; van Dam JL; Bonsing BA; Bos H; Bosscha KP; Coene PPLO; van Eijck CHJ; de Hingh IHJT; Karsten TM; van der Kolk MB; Patijn GA; Liem MSL; van Santvoort HC; Loosveld OJL; de Vos-Geelen J; Zonderhuis BM; Homs MYV; van Tienhoven G; Besselink MG; Wilmink JW; Groot Koerkamp B;
    BMC Cancer; 2021 Mar; 21(1):300. PubMed ID: 33757440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer.
    Borggreve AS; Heethuis SE; Boekhoff MR; Goense L; van Rossum PSN; Brosens LAA; van Lier ALHMW; van Hillegersberg R; Lagendijk JJW; Mook S; Ruurda JP; Meijer GJ
    Eur Radiol; 2020 Apr; 30(4):1896-1907. PubMed ID: 31822974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
    Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
    Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of neoadjuvant therapy for resectable locally advanced thoracic esophageal squamous cell carcinoma in an analysis of 5016 patients from 305 designated cancer care hospitals in Japan.
    Tsukada Y; Higashi T; Shimada H; Kikuchi Y; Terahara A
    Int J Clin Oncol; 2018 Feb; 23(1):81-91. PubMed ID: 28795280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.
    He J; Lv N; Yang Z; Luo Y; Zhong W; Wu C
    Int J Surg; 2024 Jun; 110(6):3900-3909. PubMed ID: 38935819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma.
    Cheng D; Zhao W; Chen R; Li D; Tang S; Fang C; Ji M
    World J Surg Oncol; 2023 Feb; 21(1):33. PubMed ID: 36737768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary Results of Temporary Placement of Retrievable Expandable Metallic Stents during Preoperative Neoadjuvant Chemoradiotherapy in Patients with Resectable Esophageal Cancer.
    Park JH; Song HY; Shin JH; Kim JH; Kim YH; Kim SB; Kim JH
    J Vasc Interv Radiol; 2015 Jun; 26(6):883-8. PubMed ID: 25724088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
    Eyck BM; van Lanschot JJB; Hulshof MCCM; van der Wilk BJ; Shapiro J; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch OR; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Spillenaar Bilgen EJ; van der Sangen MJC; Rozema T; Ten Kate FJW; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
    J Clin Oncol; 2021 Jun; 39(18):1995-2004. PubMed ID: 33891478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Neoadjuvant Chemoradiotherapy Followed by Surgery for Borderline Resectable Esophageal Squamous Cell Carcinoma.
    Hirohata R; Hamai Y; Hihara J; Emi M; Kurokawa T; Yoshikawa T; Ohsawa M; Kitasaki N; Okada M
    World J Surg; 2022 Aug; 46(8):1934-1943. PubMed ID: 35508816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical intervention after neoadjuvant therapy in esophageal cancer: a narrative review.
    Ke J; Xie Y; Liang J; Wang M; Lin W
    J Thorac Dis; 2023 Apr; 15(4):2261-2276. PubMed ID: 37197518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.